Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of molnupiravir in non-hospitalized high-risk adults with COVID-19
2023-507227-36-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir with Matching placebo (2 arms). Primary endpoints: Percentage of participants with hospitalization, all-cause mortality, or COVID-19-related medically attended visit through Day 29, Percentage of participants with an adverse event and 1 more. Planned start Feb 2025; status: authorised.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-507227-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507227-36-00.